Expression of glutathione S-transferase π and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung

Human Pathology

Volumn 38, Issue 2, 2007, Pages 220-227

  Allen, Timothy C ^a   Granville, Laura A ^b   Cagle, Philip T ^c   Haque, Abida ^c   Zander, Dani S ^d   Barrios, Roberto ^c  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Glutathione; Glutathione S transferase ; GSH2; GST ; Lung carcinoma; NSCLC

Indexed keywords

GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; REACTIVE OXYGEN METABOLITE; TOBACCO SMOKE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ANALYSIS; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE SYNTHASE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 33846233486     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.07.006     Document Type: Article

References (67)

1. Rushmore T.H., and Pickett C.B. Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem 268 (1993) 11475-11478
2. Armstrong R.N. Glutathione S-transferases: structure and mechanism of an archetypical detoxication enzyme. Adv Enzymol Relat Areas Mol Biol 69 (1994) 1-44
3. Lu S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 13 (1999) 1169-1183
4. Ketterer B. A bird's eye view of the glutathione transferase field. Chem Biol Interact 138 (2001) 27-42
5. Chwals W.J. Regulation of the cellular and physiological effects of glutamine. Mini Rev Med Chem 4 (2004) 833-838
6. Townsend D.M., Findlay V.L., and Tew K.D. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol 401 (2005) 287-307
7. Zappacosta B., Persichilli S., Minucci A., et al. Effect of cigarette smoke extract on the polymorphonuclear leukocytes chemiluminescence: influence of a filter containing glutathione. Luminescence 20 (2005) 73-75
8. Fidan F., Unlu M., Kiken T., et al. Oxidant-antioxidant status and pulmonary function in welding workers. J Occup Health 47 (2005) 286-292
9. Burg D., and Mulder G.J. Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev 34 (2002) 821-863
10. Ohtake Y., and Yabuuchi S. Molecular cloning of the gamma-glutamylcysteine synthetase gene of Saccharomyces cerevisiae. Yeast 7 (1991) 953-961
11. Gushima H., Yasuda S., Soeda E., Yokota M., Kondo M., and Kimura A. Complete nucleotide sequence of the E. coli glutathione synthetase Gsh-II. Nucleic Acids Res 12 (1984) 9299-9307
12. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 1998;24:111-112:1-14.
13. Armstrong R.N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 10 (1997) 2-18
14. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Bio 30 (1995) 445-600
15. Norppa H. Cytogenetic biomarkers and genetic polymorphisms. Toxicology Letters 149 (2004) 309-334
16. Miller D.P., Neuberg D., de Vivo I., et al. Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. Epidemiology 14 (2003) 545-551
17. Russo A.L., Thiagalingam A., Pan H., et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 11 (2005) 2466-2470
18. Cote M.L., Kardia S.L., Wenzlaff A.S., Land S.J., and Schwartz A.G. Combinations of glutathione S-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Carcinogenesis 26 (2005) 1158
19. Townsend D.M., and Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22 (2003) 7369-7375
20. Cullen K.J., Newkirk K.A., Schumaker L.M., et al. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma lines and primary tumors. Cancer Res 63 (2003) 8097-8102
21. Nishimura T., Newkirk K., Sessions R., et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum based chemotherapy in head and neck cancer. Clin Cancer Res 2 (1996) 1238-1243
22. Shiga H., Heath E.I., Rasmussen A.A., et al. Prognostic value of p53, glutathione S-transferase π and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5 (1999) 4097-4104
23. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54 (1994) 4313-4320
24. Shen H., Kauvar L., and Tew K.D. Importance of glutathione and associated enzymes in drug response. Oncol Res 9 (1997) 295-302
25. Duvoix A., Schmitz M., Schnekenburger M., et al. Transcriptional regulation of glutathione S-transferase P1-1 in human leukemia. Biofactors 17 (2003) 131-138
26. Cookson M.S., Reuter V.E., Linkov I., and Fair W.R. Glutathione S-transferase pi class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 47 (1995) 271-330
27. Inoue T., Ishida T., Sugio K., et al. Glutathione S-transferase pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 62 (1995) 23-27
28. Sauerbrey A., Zintl F., and Volm M. P-glycoprotein and glutathione S transferase π in childhood acute lymphoblastic leukemia. Br J Cancer 70 (1994) 1144-1149
29. Toffoli G., Frustaci S., Tumiotto L., et al. Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 3 (1992) 63-69
30. Monden N., Abe S., Sutoh I., et al. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 54 (1997) 391-399
31. Nakagawa K., Saijo N., Tsuchida S., et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265 (1990) 4296-4301
32. Hao X.Y., Bergh J., Brodin O., et al. Acquired-resistance to cisplatin and doxorubicin in a small-cell lung-cancer cell-line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 15 (1994) 1167-1173
33. Harbottle A., Daly A.K., Atherton K., and Campbell F.C. Role of glutathione S-transferase pi, p-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 92 (2001) 777-783
34. Morrow J.A. Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase-pi (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol 56 (1998) 1013-1021
35. Moscow J.A. Elevation of π class glutathione transferase activity in human breast cancer cells by transfection of the GSTπ gene and its effect on sensitivity to toxins. Mol Pharmacol 36 (1989) 22-28
36. Masanek U. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 8 (1997) 189-198
37. Puchalski R.B., and Fahl W.E. Expression of recombinant glutathione S-transferase π, Ya, or Yb1 confers resistance to alkylating agents. Med Sci 87 (1990) 2443-2447
38. Lung. American Joint Committee on Cancer: AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven Publishers, Philadelphia (Pa) 127-137
39. Chen X, Carystinos GD, Batist G. Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 1998;111-112:263-75.
40. Geroni C., Marchini S., Cozzi P., et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 62 (2002) 2332-2336
41. Tew K.D. TLK-286: a novel glutathione S-tranferase-activated prodrug. Expert Opin Investig Drugs 14 (2005) 1047-1054
42. Huang J., Tan P.H., Thiyagarajan J., and Bay B.H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 16 (2003) 558-565
43. Katahira T., Takayama T., Miyanishi K., et al. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Clin Cancer Res 10 (2004) 7934-7940
44. Su F., HU X., Jia W., et al. Glutathione S-transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 113 (2003) 102-108
45. Ribrag V., Koscielny S., Carpiuc I., et al. Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. Leukemia 17 (2003) 972-977
46. Bennaceur-Griscelli A., Bosq J., Koscielny S., et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10 (2004) 3029-3034
47. Hirano T., Kato H., Maeda M., et al. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker. Int J Cancer 117 (2005) 460-468
48. Kamada K., Goto S., Okunaga T., et al. Nuclear glutathione S-transferase π prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products. Free Radic Biol Med 37 (2004) 1875-1884
49. Shiratori Y., Soma Y., Maruyama H., et al. Immunohistochemical detection of the placental form of glutathione S-transferase in dysplastic and neoplastic human uterine cervix lesions. Cancer Res 47 (1987) 6806-6809
50. Ali-Osman F., Brunner J.M., Kutluk T.M., et al. Prognostic significance of glutathione S-transferase π expression and subcellular localization in human gliomas. Clin Cancer Res 3 (1997) 2253-2261
51. Goto S., Kamada K., Hoh Y., et al. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93 (2002) 1047-1056
52. Soh Y., Goto S., Kitajima M., et al. Nuclear localization of glutathione S-tranferase pi is an evaluation factor for drug resistance in gynaecologic cancers. Clin Oncol (R Coll Radiol) 17 (2005) 264-270
53. Calatozzolo C., Gelati M., Cuisani E., et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5, and GST-π in human glioma. J Neuro-oncology 74 (2005) 113-121
54. Chan Q.K.Y., Khoo U.S., Chan K.Y.K., et al. Promoter methylation and differential expression of π-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7 (2005) 8-16
55. Bradender J., Lord R.V., Wickramasinghe K., et al. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 6 (2002) 359-367
56. Lu C., Spitz M.R., Zhao H., et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinomas. Cancer 106 (2006) 441-447
57. Rothnie A., Callaghan R., Deeley R.G., and Cole S.P.C. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J Biol Chem 281 (2006) 13906-13914
58. Loe D.W., Almquist K.C., Deeley R.G., and Cole S.P.C. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271 (1996) 9675-9682
59. Qian Y.M., Song W.C., Cui H., et al. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem 276 (2001) 6404-6411
60. Rappa G., Lrico A., Glavell R.A., and Sartorelli A.C. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57 (1997) 5232-5237
61. Loe D.W., Deeley R.G., and Cole S.P.C. Characterization of vincristine transport by the M9r0 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58 (1998) 5130-5136
62. Renes J., de Vries E.G.E., Hienhuis E.F., et al. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharm 126 (1999) 681-688
63. Leslie E.M., Ito K., Upadhyaya P., et al. Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 276 (2001) 27846-27854
64. Peklak-Scott C., Townsend A.J., and Morrow C.S. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione S-tranferase, and MRP1. Biochemistry 44 (2005) 4426-4433
65. Morrow C.S., Peklak-Scott C., Bishwokarma B., et al. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 69 (2006) 1499-1505
66. Estrela J.M., Ortega A., and Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43 (2006) 143-181
67. Honda T., Coppola S., Ghibelli L., et al. GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther 11 (2004) 249-255